BACKGROUND: In children receiving treatment for acute myeloid leukemia (AML) there is often concern for the development of acute renal failure (ARF). Despite this, data are limited to define the incidence of ARF in this population. This study aims to evaluate the rate of ARF in AML patients and to delineate the impact of age, race, various co-morbid conditions and antimicrobial agents on the development of ARF. METHODS: A cohort of newly diagnosed AML patients from children's hospitals across the United States was identified using the Pediatric Health Information Systems database. Information regarding demographics, discharge diagnoses, pharmaceutical exposures, and hospital resource utilization were collected for each hospitalization for up to 1 year from AML diagnosis. Cox regression analysis was used to define the hazard ratios for development of ARF by demographic variables, co-morbid conditions, and exposure to various antimicrobial agents. RESULTS: Within 1 year of AML diagnosis, 135 (16.2%) patients were diagnosed with ARF. After adjustment for the presence of co-morbid conditions, the risk for ARF was greater in older patients and in black patients. Vancomycin exposure duration of greater than 48 hr and carbapenem exposure duration greater than 10 days were associated with an increased risk for ARF. CONCLUSION: ARF is a relatively common problem in children with AML. Future studies should address the different risks of ARF by age and race. Empiric therapy with potentially nephrotoxic agents did not increase the risk of nephrotoxicity. Patients on prolonged vancomycin therapy should be monitored closely for development of ARF. Copyright 2010 Wiley-Liss, Inc.
BACKGROUND: In children receiving treatment for acute myeloid leukemia (AML) there is often concern for the development of acute renal failure (ARF). Despite this, data are limited to define the incidence of ARF in this population. This study aims to evaluate the rate of ARF in AMLpatients and to delineate the impact of age, race, various co-morbid conditions and antimicrobial agents on the development of ARF. METHODS: A cohort of newly diagnosed AMLpatients from children's hospitals across the United States was identified using the Pediatric Health Information Systems database. Information regarding demographics, discharge diagnoses, pharmaceutical exposures, and hospital resource utilization were collected for each hospitalization for up to 1 year from AML diagnosis. Cox regression analysis was used to define the hazard ratios for development of ARF by demographic variables, co-morbid conditions, and exposure to various antimicrobial agents. RESULTS: Within 1 year of AML diagnosis, 135 (16.2%) patients were diagnosed with ARF. After adjustment for the presence of co-morbid conditions, the risk for ARF was greater in older patients and in black patients. Vancomycin exposure duration of greater than 48 hr and carbapenem exposure duration greater than 10 days were associated with an increased risk for ARF. CONCLUSION:ARF is a relatively common problem in children with AML. Future studies should address the different risks of ARF by age and race. Empiric therapy with potentially nephrotoxic agents did not increase the risk of nephrotoxicity. Patients on prolonged vancomycin therapy should be monitored closely for development of ARF. Copyright 2010 Wiley-Liss, Inc.
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: S M Davies; L L Robison; J D Buckley; T Tjoa; W G Woods; G A Radloff; J A Ross; J P Perentesis Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: Marko Kavcic; Brian T Fisher; Yimei Li; Alix E Seif; Kari Torp; Dana M Walker; Yuan-Shung Huang; Grace E Lee; Sarah K Tasian; Marijana Vujkovic; Rochelle Bagatell; Richard Aplenc Journal: Cancer Date: 2013-02-21 Impact factor: 6.860
Authors: Jennifer J Wilkes; Sean Hennessy; Rui Xiao; Susan Rheingold; Alix E Seif; Yuan-Shung Huang; Neika Vendetti; Yimei Li; Rochelle Bagatell; Richard Aplenc; Brian T Fisher Journal: Clin Lymphoma Myeloma Leuk Date: 2016-05-04
Authors: R Aplenc; B T Fisher; Y S Huang; Y Li; T A Alonzo; R B Gerbing; M Hall; D Bertoch; R Keren; A E Seif; L Sung; P C Adamson; A Gamis Journal: Pharmacoepidemiol Drug Saf Date: 2012-05 Impact factor: 2.890
Authors: Tamara P Miller; Andrea B Troxel; Yimei Li; Yuan-Shung Huang; Todd A Alonzo; Robert B Gerbing; Matt Hall; Kari Torp; Brian T Fisher; Rochelle Bagatell; Alix E Seif; Lillian Sung; Alan Gamis; David Rubin; Selina Luger; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2015-03-11 Impact factor: 3.167
Authors: Brian T Fisher; Sonia Singh; Yuan-Shung Huang; Yimei Li; John Gregory; Dana Walker; Alix E Seif; Marko Kavcic; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2013-07-18 Impact factor: 3.167
Authors: Alix E Seif; Brian T Fisher; Yimei Li; Kari Torp; Douglas P Rheam; Yuan-Shung V Huang; Tracey Harris; Ami Shah; Matthew Hall; Evan S Fieldston; Marko Kavcic; Marijana Vujkovic; L Charles Bailey; Leslie S Kersun; Anne F Reilly; Susan R Rheingold; Dana M Walker; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2013-11-19 Impact factor: 3.167
Authors: Marko Kavcic; Brian T Fisher; Kari Torp; Yimei Li; Yuan-Shung Huang; Alix E Seif; Marijana Vujkovic; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2012-11-28 Impact factor: 3.167